Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.66 USD -0.45 (-0.69%)
Official Closing Price Updated: 7:59 PM EDT, Apr 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,909,100
Open 65.06
Bid (Size) 64.37 (1)
Ask (Size) 64.83 (4)
Prev. Close 65.11
Today's Range 64.35 - 65.11
52wk Range 56.56 - 85.79
Shares Outstanding 1,300,260,832
Dividend Yield 4.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metasta
Trodelvy® is the first treatment for metastatic triple-negative breast cancer shown to improve progression-free survival and overall survival 
From PR Newswire
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert

Performance

YTD
+7.57%
+7.57%
1 Month
+2.52%
+2.52%
3 Month
+3.44%
+3.44%
6 Month
+0.17%
+0.17%
1 Year
-14.11%
-14.11%

More News

Read More
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
From PR Newswire
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
From Business Wire News Releases
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
From PR Newswire
Notable Monday Option Activity: FAST, GILD, WMT
Tags Stocks
From Market News Video
A Look Into Gilead Sciences Price Over Earnings
Tags GILD Markets Intraday Update
From Benzinga
Biotech Stocks Could Use A Win — Will The First Quarter Offer That?
From Investor's Business Daily
Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer
Tags General FDA Briefs
From Benzinga
Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators
Tags oncology Benzinga PGEN
From Benzinga
Novel Cancer Therapy Phase 3 Trial Expects To Be Completed Shortly
Tags Small Cap Emerging Markets Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.